In a combination therapy, CD103 expression was upregulated on cytotoxic T cells, and it is correlated with tumour reduction as CD103 on CTLs improves TCR antigen sensitivity and enables faster cancer recognition and rapid anti-tumour cytotoxicity (Qu et al., 2020; Abd Hamid et al., 2020). This evidence concerns the gene ITGAE and cancer.